A multicenter mixed-methods study on the effects of intermittent fasting in patients with immune thrombocytopenia receiving thrombopoietin receptor agonists
Author | Yassin, Mohamed A. |
Author | AlRasheed, Muna |
Author | Al-Eisa, Taghreed |
Author | Alhashim, Noura |
Author | Alsayegh, Fiasal |
Author | Abouzeid, Tarek E. |
Author | Abd El Fattah, Mohamed |
Author | Alfili, Maryam |
Author | Shalaby, Neveen |
Author | Alotaibi, Abdullah |
Author | Aljuwaisri, Nourah |
Author | Almasbahi, Anwar |
Author | Saleeb, Rii |
Author | Abdelaziz, Hend |
Author | Alshurafa, Awni |
Author | Ismail, Omar |
Author | Ghasoub, Rola |
Available date | 2025-05-27T05:41:23Z |
Publication Date | 2025 |
Publication Name | Frontiers in Nutrition |
Resource | Scopus |
Identifier | http://dx.doi.org/10.3389/fnut.2025.1434484 |
ISSN | 2296861X |
Abstract | Introduction: In recent years, significant advances have been made in the treatment of immune thrombocytopenia (ITP) with the development of thrombopoietin receptor agonists (TPO-RAs). TPO-RAs are often used following the failure of prior therapies or when bleeding episodes persist despite glucocorticoid use. In Muslim countries, where religious observance includes 16/8 intermittent fasting, the timing of medication administration may be affected. This study is the first to evaluate the impact of Ramadan fasting on patients receiving different TPO-RAs. Methods: A multicenter mixed-design study was performed in which Muslim patients who fasted during Ramadan while receiving TPO-RAs were interviewed between 2015 and 2023. Patient responses before, during, and after Ramadan were evaluated retrospectively. The bleeding tendency was assessed as (1) no bleeding, (2) minor cutaneous/mucosal bleeding, or (3) severe bleeding that involves major organs. Results: The present study included 100 patients from three Muslim countries, including Qatar, Kuwait, and Saudi Arabia, across four tertiary centers. A complete response was observed in 63% of patients on ROM, 46% on ELT and 37% on AVA. For AVA, the mean platelet (PLT) count before Ramadan was estimated at [146.11 ± 111.76], while during Ramadan, it dropped to [131.7 ± 107.6]. For patients on ELT, the mean PLT count before Ramadan was estimated at [120.02 ± 59.7], while during Ramadan, it dropped to [100.8 ± 68.16] (p = 0.016). For patients on ROM, the mean platelet count before Ramadan was estimated at [122.68 ± 80.57], while during Ramadan, it was [130.94 ± 84.96]. Only 3% (3 patients on ELT) experienced bleeding episodes. Conclusion: This study supports the feasibility of Ramadan fasting for ITP patients receiving TPO-RAs. Further studies with a larger sample size are recommended to investigate the impact of other types of fasting on the efficacy and safety of TPO-RAs. |
Sponsor | The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Publication funded by SOBI. |
Language | en |
Publisher | Frontiers Media SA |
Subject | avatrombopag eltrombopag fasting Immune thrombocytopenia intermittent fasting romiplostim thrombopoietin receptor agonist |
Type | Article |
Volume Number | 12 |
Files in this item
This item appears in the following Collection(s)
-
Medicine Research [1794 items ]